|Summary sheet: 5-MeO-MiPT|
|Molecular structure of 5-MeO-MiPT.|
|Common names||5-MeO-MiPT, Moxy|
|Psychoactive class||Psychedelic, Entactogen|
|Routes of Administration|
5-Methoxy-N-methyl-N-isopropyltryptamine (also known as 5-MeO-MiPT or colloquially as Moxy) is a psychedelic substance of the tryptamine chemical class that produces psychedelic, stimulating and mild entactogenic effects when administered. It has structural and pharmacodynamic properties similar to the drugs 5-MeO-DiPT, DiPT, and MiPT.
5-MeO-MiPT has no history of human usage prior to the 1985 publication of its synthesis and pharmacology in the Journal of Medicinal Chemistry by Repke, Grotjahn & Shulgin.
Today, it is used as a recreational drug and an entheogen, rarely sold on the streets and almost exclusively distributed as a gray area research chemical by online vendors.
- 1 Chemistry
- 2 Pharmacology
- 3 Routes of administration
- 4 Subjective effects
- 5 Toxicity and harm potential
- 6 Legal status
- 7 See also
- 8 External links
- 9 References
5-MeO-MiPT or 5-methoxy-N-methyl-N-isopropyltryptamine is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 5-MeO-MiPT is substituted at R5 of its indole heterocycle with a methoxy (MeO) functional group CH3O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT). 5-MeO-MiPT is the N-substituted isopropyl homologue of 5-MeO-DMT.
5-MeO-MiPT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist and additional mechanisms of action such as the inhibition of MAO (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically.
Routes of administration
This substance can be taken via oral ingestion or it can be smoked. When ingested orally the experience puts more of an emphasis on visual effects but can be broken up into two stages; the first half of the trip feels stimulating and entactogenic whilst the second half feels more similar to a traditional tryptamine psychedelic.
If smoked however these stages of experience are not present and the experience places more of an emphasis on physically and cognitively stimulating effects accompanied by subtle and mild changes in visual perception.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.
- Stimulating and Sedation - At dosages below 10 to 15mg, this compound's stimulating energy levels are comparable to that of LSD. However, at dosages above 15mg the compound can become very sedating in a manner which is similar to LSA.
- Spontaneous physical sensations - The "body high" of 5-MeO-MiPT can be described as a pleasurable, warm, soft and all-encompassing glow. There is also a cold, sharp tingling sensation that is manifested spontaneously at different unpredictable points throughout the trip but for others can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
- Nausea - As the user begins to come up, nausea is not uncommon and can sometimes result in initial vomiting, but typically fades past this point. In comparison to other psychedelics such as psilocin, LSD, and 2C-E, this could actually be considered very mild in its intensity. In comparison to 5-MeO-DIPT, this substance has a much lower tendency to trigger unpleasant physical reactions and has been described as much less physically stimulating.
- Bodily pressures
- Abnormal heart beat
- Increased heart rate
- Increased blood pressure
- Stomach bloating - At higher dosages, this compound can induce severe stomach bloating within those who are susceptible to it. This can be partially to fully mitigated through the use of antacids.
- Pupil dilation
- Drifting (Melting, Breathing, Warping and Flowing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion and static in appearance.
- After images
- Symmetrical texture repetition
- Colour shifting
- Scenery slicing
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of Psilocin, 4-AcO-DMT or ayahuasca than that of LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in feel, brightly lit, multicoloured in scheme, glossy in shading, equal in blurred and sharp edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and progressive in intensity. At higher dosages they are significantly more likely to result in states of level 8B visual geometry over level 8A.
5-MeO-MiPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
- Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) - In comparison to other psychedelics such as LSD, 5-MeO-MiPT is extremely high in hallucinations at appropriate dosages. These are more common in darkness and can be comprehensibly described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
At low to moderate dosages, the cognitive effects of 5-MeO-MiPT are often described by many as both insightful and moderately relaxing, but at some points quite stimulating. This substance produces a large number of typical psychedelic cognitive effects which progressively intensify proportional to dosage. At higher dosages, however, it becomes primarily sedating and impairing with depersonalization and no accompanying insight.
- Analysis enhancement - This component is Introspection dominant and consistently manifested only in the context of a non-social setting in which the user is alone.
- Empathy, affection, and sociability enhancement - This component is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than those found on substances such as MDMA and 2C-B but still prove strong enough to provide long-lasting therapeutic effects.
- Depersonalization - Unlike most traditional psychedelics, 5-MeO-MiPT can cause extreme depersonalization and dissociation for some users throughout the duration of the experience.
- Conceptual thinking
- Increased music appreciation
- Emotion enhancement
- Increased libido
- Memory suppression
- Novelty enhancement
- Personal bias suppression
- Thought acceleration
- Thought connectivity
- Time distortion
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational 5-MeO-MiPT do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-MiPT is a research chemical with very little history of human usage.
Anecdotal evidence from people within the community who have tried 5-MeO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
5-MeO-MiPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 5-MeO-MiPT are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-MiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-MiPT all psychedelics will have a reduced effect.
There are no known deaths from 5-MeO-MiPT but, as a monoamine reuptake inhibitor (MRI), injury could occur when excessive doses are taken or when it is taken with drugs such as MAOIs, RIMAs, stimulants and any substance which act as a releasing agent or reuptake inhibitor of neurotransmitters such as serotonin and dopamine.
- United States: 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of 5-MeO-DiPT, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- United Kingdom: 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.
- Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
- Romania: 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.
- Japan: 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.
- Latvia: 5-MeO-MiPT is a Schedule I drug.
- China: The drug is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.
- Finland: 5-MeO-MiPT was banned in Finland in December 2014.
- New Zealand: 5-MeO-MiPT is an analogue of DMT, so is a Class C controlled drug in New Zealand.
- 5-MeO-MiPT (Wikipedia)
- 5-MeO-MiPT (Erowid)
- 5-MeO-MiPT (TiHKAL)
- 5-MeO-MiPT (TripSit)
- 5-MeO-MiPT (Bluelight)
- The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811
- Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents | http://pubs.acs.org/doi/abs/10.1021/jm00145a007
- The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17223101
- Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
- The 2015 Florida Statutes - Title XLVI CRIMES - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL | http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html
- 5-MeO-MiPT Legal Status by Erowid | https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_law.shtml
- 2015 Minnesota Statutes | https://www.revisor.mn.gov/statutes/?id=152.02
- Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3
- Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) | http://likumi.lv/doc.php?id=121086
- Erowid China Psychoactive Law Update: September 2015 | https://www.erowid.org/psychoactives/law/countries/china/china_law_2015_09_27_list_of_newly_controlled_chemicals.pdf
- Finland's Prohibited Psychoactive Substances: December 19, 2014. https://www.erowid.org/psychoactives/law/countries/finland/finland_law1_2014.pdf